Trial Profile
A phase II, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the safety and efficacy of rituximab (Mabthera/Rituxan) in adults with relapsing remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms HERMES
- Sponsors Genentech
- 14 Feb 2008 Results have been published in the New England Journal of Medicine.
- 15 Oct 2007 Status changed from in progress to completed.
- 13 Oct 2007 Results have been reported at ECTRMS 2007